Novelli A, Ulivelli A, Reali E F, Mannelli F, Trombi Belcari L, Spezia R, Periti P
Chemioterapia. 1984 Jun;3(3):152-5.
The commercial preparation of Bacillus subtilis spores may be considered within the classification of biological response modifiers (BRM's) and included among exogenous natural substances. Recently we decided to study the effect of a long-term B. subtilis spores oral treatment in children suffering from recurrent infectious diseases of the respiratory tract. Fifty-three children 5-9 years old have been studied. The clinical valuative parameter was the number of days of absence from school during a 4-month period. In another group of 12 diseased children, mean age 5.5 yrs we recently initiated a laboratory immunological evaluation of peripheral lymphomonocytes in relation to an oral treatment with B. subtilis spores for at least 2 months. Our results show that B. subtilis spore therapy significantly reduced the frequency of respiratory tract infections in the group of treated children. In addition, preliminary immunological laboratory evaluation demonstrated a complete return to the normal lymphomonocyte status after at least 2 months of treatment with B. subtilis spores.
枯草芽孢杆菌孢子的商业制剂可被视为生物反应调节剂(BRM)分类中的一种,并被列入外源性天然物质之中。最近,我们决定研究长期口服枯草芽孢杆菌孢子对患有复发性呼吸道传染病儿童的影响。我们对53名5至9岁的儿童进行了研究。临床评估参数是4个月期间缺课的天数。在另一组12名患病儿童中,平均年龄5.5岁,我们最近开始对与口服枯草芽孢杆菌孢子至少2个月相关的外周淋巴细胞进行实验室免疫学评估。我们的结果表明,枯草芽孢杆菌孢子疗法显著降低了治疗组儿童呼吸道感染的频率。此外,初步的免疫学实验室评估表明,在用枯草芽孢杆菌孢子治疗至少2个月后,淋巴细胞状态完全恢复正常。